Cellular Origins
Regenerative Medicine · Cell & Gene Therapy
Venture roundlatest round · Nov 2025 · 11 mo ago
2backers · BGF, Highland Europe
$609kgrants · 1 grant · CORDIS
50+team · employees, estimated range
Overview
Constellation® is an automated cell therapy manufacturing platform that enables scalable, flexible production without therapy redevelopment or comparability risk.
Key facts
These are the key facts about Cellular Origins on Alion as of Nov 13, 2026. Cellular Origins is headquartered in Melbourn, United Kingdom. It was founded in 2022.
- Headquarters
- Melbourn, United KingdomAlion company profile, updated Nov 3, 2026
- Founded
- 2022Alion company profile, updated Nov 3, 2026
- Employees
- 50+Alion company profile, an estimated range
Official records
Funding and backers
Latest round
Venture round
Nov 2025 · 11 mo ago
Team
51-200
employees, estimated range
Grants
$609k
1 grant · CORDIS
Backers
2
BGF, Highland Europe
The money's age
Fresh money
11 months since the last round · not hiring
Momentum
35/100
in the news, fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Nov 24, 2025
Raised a round Venture round
Jul 1, 2025
Won a grant $609k · CORDIS
May 28, 2024
Partnership Cellular Origins and Cell and Gene Therapy Catapult Collaborate to Demonstrate Universal Automation of CGT Manufacturing · businesswire.com
Jan 24, 2024
New executive Cellular Origins, a TTP Company, Appoints Peter Crossley as Chief Operating Officer · streetinsider.com
Feb 11, 2022
Founded per the company register
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Nov 2025 | — | — | find-and-update.company-information.service.gov.uk |
| Grant | Jul 2025 | $609k | — | CORDIS |
Registers and programsofficial lists and records that name the company
| Legal entity | CELLULAR ORIGINS LIMITED | Companies House |
| Registered | 11 Feb 2022 |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
セレイドセラピューティクス - 細胞治療(造血幹細胞). Change the futurewith cell therapy.
Advance your cell therapy with Cellipont Bioservices, a leading cell therapy CDMO, offering tailored development, analytics, and cGMP…
CellBri's automated cell processing systems simplify manufacturing, reduce risk, and accelerate your path to clinic. Modular or all-in-one…
Shinobi Therapeutics is transforming cell therapy with scalable, immune-evasive iPSC-derived treatments for cancer and autoimmune diseases.
Avigen develops cellular avidity tools for immunotherapy and cell therapy R&D, helping identify potent and safe lead drug candidates faster.
Our CELLfinity platform is delivering safe in vivo cell & gene therapies that is based on our proprietary EXiVO approach, without…
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Highland EuropeVia a fund
BGFVia a fund
406 portfolio companies
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
Autolomous and Cellular Origins expand platform integration to deliver end-to-end cell therapy manufacturing orchestration
Autolomous and Cellular Origins today announce end-to-end integration of their respective platforms, bringing full automation and digitization to the entire cell therapy manufacturing process.
Read more
Report
Fresenius Kabi and Cellular Origins agree CGT manufacture automation
The initiative aims to enhance production efficiency and reduce the risk of human error-induced inconsistencies.
Read more
Report
Cellular Origins, Fresenius Kabi sign development agreement for scalable automation of cell and gene therapy manufacturing
Cellular Origins and Fresenius Kabi, an operating company of Fresenius, announce today they have signed a development agreement that leverages each company's expertise in cell and gene therapies (CGTs).
Read more
Report
Cellular Origins, Fresenius Kabi Sign Development Agreement for Scalable Automation of Cell and Gene Therapy Manufacturing
Read more
Report
Cellular Origins, Fresenius Kabi Sign Development Agreement for Scalable Automation of Cell and Gene Therapy Manufacturing
Read more
Report
Cellular Origins acquires Actia Platform IP to enhance automated cell therapy manufacturing
Cellular Origins, a TTP Company, focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), today announced the acquisition of the ACTIA (Autologous Cell Therapy Industrial Automation) Platform IP, developed
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Melbourn
United Kingdom
HQ
Global Headquarters.
50-200 est. staff
TTP Campus, Melbourn Science Park, Melbourn, SG8 6HQ, UK
How to cite this page
Alion, "Cellular Origins: key facts", as of Nov 13, 2026. https://alion.io/company/cellularorigins
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0